Lambert-Eaton myasthenic syndrome
Neurology · 2021–2022
2decisions
1medicine
2carried consumer input
27individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| amifampridine Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged 6 years and above. | Mar 2022 | Recommended with restriction | 9 individuals |
| amifampridine Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged 6 years and above, including paraneoplastic LEMS (pLEMS) and autoimmune LEMS… | Nov 2021 | Not recommended | 18 individuals Myasthenia Alliance |
Who spoke
Myasthenia Alliance
What the PBS pays
$3M in government benefit over 2024–25, across 532 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| amifampridine | $2.5M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.